RE:messageattachment to message
Toronto, Ontario – TheNewswire – April 13, 2021 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) has published its first case study of the meritorious use of the Ventripoint VMS whole-heart analysis system ( https://www.ventripoint.com/whitepapers-case-studies ) in routine clinical practice.
Dr. Gregory Skinner at East Midlands Congenital Heart Centre, Leicester, England documents a case of two patients with Tetralogy of Fallot (ToF), which developed significant right ventricular (RV) dilation due to pulmonary valve dysfunction. The case studies highlight the need for repeated accurate assessments of RV size and function to determine the optimal time for valve replacement and evaluate the outcome. The remodeling of the RV towards a normal size after surgical implantation of the pulmonary valve signifies the RV has not been left too long in the dilated state. In one case the RV remodeled (shrunk) and in the other case it did not.
A series of case studies and white papers will be published over the next several months to showcase various limitations of current clinical practice, which are overcome by the VMS family of products. Coming topics include user experience perspectives, usability of the VMS products, and VMS use in patients infected with COVID-19.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Dr. George Adams